You are here

Lesley Mathews Griner

Publications

Ramurthy S, Taft BR, Aversa RJ, et al. Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. J Med Chem. 2020;63(5):2013-2027. doi:10.1021/acs.jmedchem.9b00161

 

Lesley Mathews Griner, Ph.D.

Lesley Mathews Griner is an associate director of translational pharmacology/cellular pharmacology in the Center for the Development of Therapeutics (CDoT), where she reports to director Oivin Guicherit. Griner joined in November of 2020. Within the cellular pharmacology team she helps to drive the development of new drugs and tests their behavior in cellular model systems with the ultimate goal of establishing in vivo proof of concept. Griner co-leads a number of drug discovery projects which stem from the PRISM lab and works closely with CDoT collaborators from a variety of companies and investment firms. She also leads a lab of research scientists, research associates, and interns.

Prior to joining the Broad, Griner worked at the Novartis Institutes for Biomedical Research (NIBR), where she was a lead investigator in oncology and a teacher in their community exploration learning lab. Griner designed the Introduction to Making of Medicine Course at Novartis and was awarded their Diversity and Inclusion Award in 2016. Prior to that, she was a research scientist at the National Center for Advancing Translational Sciences at the National Institutes of Health, where she started a program to study drug-drug combinations. Griner was awarded a fellowship for young women in science at the National Institutes of Health (NIH)-National Cancer Institute (NCI) where she continued her studies in the regulation and druggability of cancer. 

Griner holds a bachelor’s degree in biology from Clark University and a master’s degree in education from Lesley University. She earned a doctorate in cellular and molecular biology from the University of Massachusetts, Amherst, studying pregnancy and breast cancer.

November 2022